<?xml version="1.0" encoding="UTF-8"?>
<p id="Par10">Management of chronic therapies was also challenging. The role of ACE-2 receptor in SARS-CoV-2 cell entry process produced a lively debate on the potential impact of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin II receptor blockers (ARBs), extensively used for the treatment of hypertension and other cardiovascular diseases, on the natural history of SARS-Cov-2 infection. Two papers of the Topical Collection explored the potential implication of ACE-Is and ARBs use in Covid-19 patients [
 <xref ref-type="bibr" rid="CR36">36</xref>, 
 <xref ref-type="bibr" rid="CR37">37</xref>]. Finally, Testa et al. addressed the management of Covid-19 patients on oral anticoagulant drugs, and the high risk of over/under treatment due to the multiple pharmacological interactions, and the possible necessity of mechanical ventilation, and suggested replacing oral anticoagulant therapies with parenteral low-molecular-weight heparin or unfractionated heparin [
 <xref ref-type="bibr" rid="CR38">38</xref>]. On the other hand, a paper by Poli et al. provided some advice aimed at improving the outpatient management of people on anticoagulant treatment during COVID-19 pandemic, with particular regard to the lockdown and reopening periods [
 <xref ref-type="bibr" rid="CR39">39</xref>].
</p>
